Print This Page
Email to a Friend
 
Binding Affinity

ALOXI® BINDS STRONG, LASTS LONG
All 5-HT3 Receptor Antagonists Are NOT the Same

HIGHLY SELECTIVE FOR THE 5-HT3 RECEPTOR1

  • Receptor binding affinity at least 30X higher than any other 5-HT3 receptor antagonist.*1,2
  • Highly selective 5-HT3 receptor antagonist, with little or no affinity for other receptors.1,3

ALOXI - 5-HT3 receptor binding affinity

*In vitro data; clinical significance has not been established.

References
  1. Wong EHF, Clark R, Leung E, et al. The interaction of RS 25259-197, a potent and selective antagonist, with 5-HT3 receptors, in vitro. Br J Pharmacol. 1995;114:851-859.
  2. Miller RC, Galvan M, Gittos MW, van Giersbergen PLM, Moser PC, Fozard JR. Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res. 1993;28:87-93.
  3. ALOXI (palonosetron HCl) injection full prescribing information.

During initial and repeat courses of chemotherapy, ALOXI helps prevent and control nausea and vomiting the day following chemotherapy that is highly likely to cause nausea and vomiting, and for up to 5 days following chemotherapy that is likely to cause nausea and vomiting. The most frequent side effects of ALOXI include headache and constipation. If you have or may develop significant heart rhythm changes, talk with your healthcare professional before receiving ALOXI.

ALOXI is available by prescription only. Please see the important product information for ALOXI for more information.

This site does not contain everything that is known about ALOXI. If you would like to know more, talk to your healthcare professional.

Prescribing Information | Sitemap | Glossary | Legal Notice | Privacy | Contact Us

This Web site is intended for U.S. residents only.

Distributed and marketed by MGI PHARMA, INC., Bloomington MN 55437
under license of Helsinn Healthcare SA, Switzerland.
© 2007 MGI PHARMA, INC., Bloomington, MN 55437 U.S.A. AL277 9/07

Please see Important Product Information.